Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.53 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.53 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.53 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1772877 | 0.90 | TAAR1 (0.56) | HTR2ASIGMAR1MAOBTAAR1HDAC1 | |
| SCHEMBL5238701 | 0.89 | TAAR1 (0.62) | HTR2ASIGMAR1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL9069707 | 0.87 | HTR2A (0.75) | HTR2ASIGMAR1MAOBHDAC8HDAC1 | |
| SCHEMBL8100045 | 0.85 | SIGMAR1 (0.76) | SIGMAR1 | |
| SCHEMBL7904900 | 0.84 | TAAR1 (0.62) | HTR2ASIGMAR1MAOBTAAR1HSP90AA1 | |
| SCHEMBL15347959 | 0.84 | HTR2A (0.71) | HTR2ASIGMAR1MAOBHDAC8HDAC1 | |
| SCHEMBL54347 | 0.84 | HTR2A (0.70) | HTR2ASIGMAR1MAOBTAAR1HDAC8 | |
| SCHEMBL15583726 | 0.81 | TAAR1 (0.59) | HTR2ASIGMAR1TAAR1HSP90AA1ALDH1A1 | |
| SCHEMBL30096319 | 0.81 | TAAR1 (0.59) | HTR2ASIGMAR1TAAR1HSP90AA1ALDH1A1 | |
| SCHEMBL134452 | 0.81 | TAAR1 (0.59) | HTR2ASIGMAR1TAAR1HSP90AA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102249879-B | 1,2-diketone derivant and preparation method thereof | UNIV ZHEJIANG | 2013-04-17 | — | — | CN | claimed |
| CN-102249879-A | 1,2-diketone derivant and preparation method thereof | UNIV ZHEJIANG | 2011-11-23 | — | — | CN | claimed |
| CN-110627626-B | Preparation method of propargyl acetone compound | 内蒙古大学 | 2022-04-26 | — | — | CN | disclosed |
| CN-110452270-B | Azacarbene palladium complex crystal, synthesis method thereof and application thereof in preparation of alpha, beta-unsaturated ketone compound | 陕西师范大学 | 2022-02-25 | — | — | CN | disclosed |
| EP-2697212-B1 | PHENYL BICYCLIC METHYL AMINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN INC (US) | 2015-09-09 | — | — | EP | disclosed |
| EP-2697212-B1 | PHENYL BICYCLIC METHYL AMINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN INC (US) | 2015-09-09 | — | — | EP | disclosed |
| EP-2729149-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | Glaxo Group Limited (GB) | 2014-05-14 | — | — | EP | disclosed |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2014-05-01 | — | — | US | disclosed |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2014-05-01 | — | — | US | disclosed |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2014-05-01 | — | — | US | disclosed |
| US-8653050-B2 | Phenyl bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators | ALLERGAN, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| CN-102249879-A | 1,2-diketone derivant and preparation method thereof | UNIV ZHEJIANG | 2011-11-23 | — | — | CN | disclosed |
| WO-2011143332-A1 | AROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHONATE (S1P) RECEPTOR ACTIVITY | ALLERGAN, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| US-20110281822-A1 | AROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHONATE (S1P) RECEPTOR ACTIVITY | ALLERGAN, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| WO-2011088201-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088201-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | WO | disclosed |
| US-20060089371-A1 | Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist | BAYER HEALTHCARE AG (DE) | 2006-04-27 | — | — | US | disclosed |
| CN-1735598-A | Phenyl or heteroaryl amino alkane derivatives as IP receptor antagonist | BAYER HEALTHCARE AG (DE) | 2006-02-15 | — | — | CN | disclosed |
| EP-1575919-A1 | PHENYL OR HETEROARYL AMINO ALKANE DERIVATIVES AS IP RECEPTOR ANTAGONIST | Bayer HealthCare AG (DE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004043926-A1 | PHENYL OR HETEROARYL AMINO ALKANE DERIVATIVES AS IP RECEPTOR ANTAGONIST | BAYER HEALTHCARE AG (DE) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | KCNB1, SCNN1B, TRPV1 | HTR2A 1008/4885SIGMAR1 1773/4885MAOB 773/4885 |
| US-20110281822-A1 | AROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHONATE (S1P) RECEPTOR ACTIVITY | S1PR1, S1PR3, S1PR2 | HTR2A 752/4885SIGMAR1 545/4885MAOB 2424/4885 |
| US-20060089371-A1 | Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist | BPHL, HRH4, HRH2 | HTR2A 138/4885SIGMAR1 268/4885MAOB 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.